After the first part of Generics Bulletin’s annual Top 50 ranking showed how the world’s 10 biggest generics and biosimilars firms had changed position in the past year, that trend has continued into the middle of the pack, as the mixed fortunes of companies occupying positions 11 to 30 have seen some rise up the rankings at the same time as others have slipped down the table.
Ups And Downs See Mid-Table Players Shift Position
Leading Industry Players Jostle In The Middle Of Our Top 50 Ranking
Mid-table players jostle for position as we continue to work our way through Generics Bulletin’s annual Top 50, with mixed fortunes over the past year seeing some companies rise up the rankings as others decline.
More from Company Rankings
• By
This article compiles all of the data from Generics Bulletin’s 2024 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.
• By
In the third instalment of this year’s Generics Bulletin Top 50, we look at some of the firms that have been eliminated from the bottom of our table as others have entered the picture.
• By
In the second part of Generics Bulletin’s Top 50, we see some companies rising up the rankings of generics and biosimilars players worldwide, passing others that are moving in the opposite direction.
• By
A deceptively familiar top 10 of generics and biosimilars industry leaders this year belies the significant evolutions seen for major off-patent players over the past 12 months. We reveal the changes under the surface in the first instalment of this year’s Generics Bulletin Top 50.
More from Market Intelligence
• By
Dementia treatment memantine saw the steepest rise in its UK trade price in November, according to the latest figures from WaveData.
• By
After a few months of steep UK price rises for apixaban generics, October saw a correction as average prices headed in the opposite direction, the latest figures from WaveData reveal.
• By
Generics of the schizophrenia treatment Latuda generated more than $4bn in savings a year after their 2022 approval, according to an FDA study.